Takeda offloads URL generics business to Caraco for $65m
This article was originally published in Scrip
In a move expected since it completed the acquisition of the private US firm in June, Takeda is divesting the generics business of URL Pharma, with the Caraco Pharmaceutical Laboratories subsidiary of India's Sun Pharmaceutical Industries emerging as the buyer.
You may also be interested in...
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.